Status:
ACTIVE_NOT_RECRUITING
Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL Combination
Lead Sponsor:
SpyGlass Pharma, Inc.
Conditions:
Glaucoma
Cataract
Eligibility:
All Genders
Brief Summary
The goal of this clinical trial is to further observe and learn if the SpyGlass Pharma Bimatoprost Implant System / IOL Combination works to treat cataracts and either ocular hypertension or glaucoma....
Eligibility Criteria
Inclusion
- Be able to understand a written informed consent and be willing to participate by evidence of signing an informed consent form
- Met all inclusion criteria, participated in and completed the SGP-SPEC-001 study
Exclusion
- Planned participation in another clinical trial within 30 days of the initial study visit that, in the investigator's opinion, could confound the study results
Key Trial Info
Start Date :
March 16 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 14 2031
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT07154810
Start Date
March 16 2023
End Date
April 14 2031
Last Update
September 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro Oftalmológico Robles
Santa Rosa de Copán, Honduras, 41101